UnknownNot Applicable

Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta

France63 participantsStarted 2013-11

Plain-language summary

The purpose of this study is to determine whether, in a high risk population (placenta praevia and previous caesarean or prenatal suspicion of morbidly adherent placenta (MAP)), the concentration of cell-free fetal DNA circulating in the maternal plasma is significantly increased in the subgroup of morbidly adherent placenta (MAP) cases , in order to determine if the dosage of cell-free fetal DNA circulating in the maternal plasma may be a useful biological tool to detect MAP, alone or in addition to the imagery findings (ultrasonography and RMI).

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Every woman: * delivering in one of the 5 maternity units that participate to a Population-based prospective observational study of pregnant women with a placenta praevia and previous cesarean or with prenatal suspicion of accreta (PACCRETA) . * With a placenta praevia and at least one previous cesarean delivery or having a prenatal suspicion of placenta accreta * aged 18 or more Exclusion Criteria: Every woman: * not understanding French. * refusing to participate in the study

What they're measuring

Concentration of cell-free fetal DNA circulating in the maternal plasma

Timeframe: from 24 weeks gestation to delivery

Trial details

NCT IDNCT02784886

SponsorUniversity Hospital, Angers

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2015-11

View on ClinicalTrials.gov More Morbidly Adherent Placenta trials